These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
389 related articles for article (PubMed ID: 263873)
61. [Immunization of healthy children with mumps-rubella bivalent live vaccine and simultaneous vaccination with mumps-rubella and varicella vaccines]. Takayama N; Kidokoro M; Suzuki K; Morita M Kansenshogaku Zasshi; 1991 Oct; 65(10):1271-5. PubMed ID: 1791323 [TBL] [Abstract][Full Text] [Related]
62. Mass vaccination programme aimed at eradicating measles, mumps and rubella in Sweden: vaccination of schoolchildren. Böttiger M; Christenson B; Taranger J; Bergman M Vaccine; 1985 Jun; 3(2):113-6. PubMed ID: 4036269 [TBL] [Abstract][Full Text] [Related]
63. Measles, mumps, and rubella antibodies in children 5-6 years after immunization: effect of vaccine type and age at vaccination. Boulianne N; De Serres G; Ratnam S; Ward BJ; Joly JR; Duval B Vaccine; 1995 Nov; 13(16):1611-6. PubMed ID: 8578850 [TBL] [Abstract][Full Text] [Related]
65. [1st results with a combined live vaccine against measles, mumps, and rubella]. Stehr K; Epp C; Spiess H Monatsschr Kinderheilkd (1902); 1975 May; 123(5):410-2. PubMed ID: 1219453 [No Abstract] [Full Text] [Related]
66. The effect of live measles vaccines on serum vitamin A levels in healthy children. Yalçin SS; Yurdakök K; Ozalp I; Coşkun T Acta Paediatr Jpn; 1998 Aug; 40(4):345-9. PubMed ID: 9745778 [TBL] [Abstract][Full Text] [Related]
67. Vaccine-induced measles virus antibodies after two doses of combined measles, mumps and rubella vaccine: a 12-year follow-up in two cohorts. Davidkin I; Valle M Vaccine; 1998 Dec; 16(20):2052-7. PubMed ID: 9796064 [TBL] [Abstract][Full Text] [Related]
68. Acute encephalopathy followed by permanent brain injury or death associated with further attenuated measles vaccines: a review of claims submitted to the National Vaccine Injury Compensation Program. Weibel RE; Caserta V; Benor DE; Evans G Pediatrics; 1998 Mar; 101(3 Pt 1):383-7. PubMed ID: 9481001 [TBL] [Abstract][Full Text] [Related]
70. Measles vaccine immunogenicity and antibody persistence in 12 vs 15-month old infants. Johnson CE; Darbari A; Darbari DS; Nalin D; Whitwell J; Chui LW; Cleves MA; Kumar ML Vaccine; 2000 May; 18(22):2411-5. PubMed ID: 10738098 [TBL] [Abstract][Full Text] [Related]
71. [Antibody formation following immunization with mono- and bivalent mumps-(measles-)vaccine (author's transl)]. Sarateanu DE; Allerdist H; Ehrengut W Immun Infekt; 1978 Feb; 6(1):33-7. PubMed ID: 627405 [TBL] [Abstract][Full Text] [Related]
72. Revaccination against measles--a pilot study. Watson GI; Nichols JA; Robshaw JR J R Coll Gen Pract; 1975 Dec; 25(161):863-73. PubMed ID: 1223275 [TBL] [Abstract][Full Text] [Related]
73. A new combined trivalent live measles (AIK-C strain), mumps (Hoshino strain), and rubella (Takahashi strain) vaccine. Findings in clinical and laboratory studies. Makino S; Sasaki K; Nakayama T; Oka S; Urano T; Kimura M; Kawana R; Yamamura AM Am J Dis Child; 1990 Aug; 144(8):905-10. PubMed ID: 2198807 [TBL] [Abstract][Full Text] [Related]
74. Antibody response to measles and rubella vaccine by children with HIV infection. Breña AE; Cooper ER; Cabral HJ; Pelton SI J Acquir Immune Defic Syndr (1988); 1993 Oct; 6(10):1125-9. PubMed ID: 8410669 [TBL] [Abstract][Full Text] [Related]
75. Evaluation of measles-rubella vaccination for mothers in early puerperal phase. Hisano M; Kato T; Inoue E; Sago H; Yamaguchi K Vaccine; 2016 Feb; 34(9):1208-14. PubMed ID: 26801065 [TBL] [Abstract][Full Text] [Related]
76. Booster vaccination with further live attenuated measles vaccine. Bass JW; Halstead SB; Fischer GW; Podgore JK; Pearl WR; Schydlower M; Wiebe RA; Ching FM JAMA; 1976 Jan; 235(1):31-4. PubMed ID: 945997 [TBL] [Abstract][Full Text] [Related]
77. Combination of attenuated measles vaccine (Schwarz) with meningococcus A and A + C vaccine. Ajjan N; Fayet MT; Biron G; Charbonnier C; Nicolas A; Triau R; Roumiantzeff M Dev Biol Stand; 1978; 41():209-16. PubMed ID: 111980 [TBL] [Abstract][Full Text] [Related]
78. A controlled trial for evaluating two live attenuated mumps-measles vaccines (Urabe Am 9-Schwarz and Jeryl Lynn-Moraten) in young children. Popow-Kraupp T; Kundi M; Ambrosch F; Vanura H; Kunz C J Med Virol; 1986 Jan; 18(1):69-79. PubMed ID: 3511182 [TBL] [Abstract][Full Text] [Related]
79. Decline of measles-specific immunoglobulin M antibodies after primary measles, mumps, and rubella vaccination. Helfand RF; Gary HE; Atkinson WL; Nordin JD; Keyserling HL; Bellini WJ Clin Diagn Lab Immunol; 1998 Mar; 5(2):135-8. PubMed ID: 9521134 [TBL] [Abstract][Full Text] [Related]
80. [Vaccination strategies of tomorrow... is it necessary to revaccinate rubella, mumps and rubeola, and when?]. Guérin N; Lévy-Bruhl D Arch Pediatr; 1998; 5 Suppl 2():187s-190s. PubMed ID: 9759256 [No Abstract] [Full Text] [Related] [Previous] [Next] [New Search]